Similar Papers

Paper Title
Journal
Date
Author
Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia
Jan Philipp Bewersdorf ... Amy J Davidoff
Blood | VOL. 136
Jan Philipp Bewersdorf, et. al.Jan Philipp Bewersdorf ... Amy J Davidoff
05 Nov 2020
Metformintreatment Overcomes ATRA-Resistance in Acute Promyelocytic Leukemia and Increases FOXO3A Expression
...
Blood | VOL. 132
, et. al. ...
29 Nov 2018
Value of Minimal Residual Disease (MRD) Monitoring Using Real-Time Quantitative PCR in Patients with Acute Promyelocytic Leukemia (APL) Treated with ATRA, ATO, +/- GO
Jorge Cortes ... Farhad Ravandi
Blood | VOL. 134
Jorge Cortes, et. al.Jorge Cortes ... Farhad Ravandi
13 Nov 2019
Administration of All-Trans Retinoic Acid (ATRA) to Newly Diagnosed Patients (pts) with Acute Promyelocytic Leukemia (APL) Is Delayed Even At Experienced Centers and Associated with An Increased Early Death Rate (EDR): A Retrospective Analysis of 205 Pts
Jessica K Altman ...
Blood | VOL. 118
Jessica K Altman, et. al.Jessica K Altman ...
18 Nov 2011
View more papers

More From: Blood

Paper Title
Journal
Date
Author
The JAK2 46/1 haplotype influences PD-L1 expression.
Gonzalo Carreño-Tarragona ... Miguel Manzanares
Blood | VOL. -
Gonzalo Carreño-Tarragona, et. al.Gonzalo Carreño-Tarragona ... Miguel Manzanares
07 Feb 2025
Targeting cell surface VISTA expression on allospecific naïve T cells promotes tolerance.
Brent H Koehn ... Bruce R Blazar
Blood | VOL. -
Brent H Koehn, et. al.Brent H Koehn ... Bruce R Blazar
07 Feb 2025
Venetoclax plus Daunorubicin and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia: Results of a Phase 1b Study.
Ioannis Mantzaris ... Eric J Feldman
Blood | VOL. -
Ioannis Mantzaris, et. al.Ioannis Mantzaris ... Eric J Feldman
07 Feb 2025
Acute myeloid leukemia with BCL6 and KMT2A dual rearrangements.
Qiudan Shen ... Shimin Hu
Blood | VOL. 145
Qiudan Shen, et. al.Qiudan Shen ... Shimin Hu
06 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.